Bionano Genomics Inc (BNGO)

$0.9775

-0.05

(-5.1%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Bionano Genomics Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 7.41M → 10.72M (in $), with an average increase of 11.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -112.56M → -43.89M (in $), with an average increase of 156.5% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 44.1% return, outperforming this stock by 135.1%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 46.9% return, outperforming this stock by 145.4%

Performance

  • $0.96
    $1.02
    $0.98
    downward going graph

    2.37%

    Downside

    Day's Volatility :6.2%

    Upside

    3.92%

    downward going graph
  • $0.96
    $11.80
    $0.98
    downward going graph

    2.03%

    Downside

    52 Weeks Volatility :91.86%

    Upside

    91.69%

    downward going graph

Returns

PeriodBionano Genomics IncSector (Health Care)Index (Russel 2000)
3 Months
-24.22%
-1.1%
0.0%
6 Months
-56.94%
6.7%
0.0%
1 Year
-91.03%
3.2%
-0.7%
3 Years
-98.48%
17.2%
-21.3%

Highlights

Market Capitalization
56.9M
Book Value
$2.1
Earnings Per Share (EPS)
-6.81
Wall Street Target Price
6.67
Profit Margin
0.0%
Operating Margin TTM
-269.97%
Return On Assets TTM
-33.39%
Return On Equity TTM
-134.56%
Revenue TTM
36.1M
Revenue Per Share TTM
1.06
Quarterly Revenue Growth YOY
30.5%
Gross Profit TTM
5.9M
EBITDA
-125.7M
Diluted Eps TTM
-6.81
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.61
EPS Estimate Next Year
-1.89
EPS Estimate Current Quarter
-0.87
EPS Estimate Next Quarter
-0.64

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Bionano Genomics Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 582.35%

Current $0.98
Target $6.67

Company Financials

FY18Y/Y Change
Revenue
12.0M
↑ 26.26%
Net Income
-18.5M
↓ 20.84%
Net Profit Margin
-154.13%
↑ 91.69%
FY19Y/Y Change
Revenue
10.1M
↓ 15.59%
Net Income
-29.8M
↑ 61.31%
Net Profit Margin
-294.55%
↓ 140.42%
FY20Y/Y Change
Revenue
8.5M
↓ 16.06%
Net Income
-41.1M
↑ 37.87%
Net Profit Margin
-483.78%
↓ 189.23%
FY21Y/Y Change
Revenue
18.0M
↑ 111.47%
Net Income
-72.4M
↑ 76.09%
Net Profit Margin
-402.84%
↑ 80.94%
FY22Y/Y Change
Revenue
27.8M
↑ 54.62%
Net Income
-132.6M
↑ 83.06%
Net Profit Margin
-476.93%
↓ 74.09%
FY23Y/Y Change
Revenue
36.1M
↑ 29.9%
Net Income
-232.5M
↑ 75.34%
Net Profit Margin
-643.74%
↓ 166.81%
Q3 FY22Q/Q Change
Revenue
7.2M
↑ 8.26%
Net Income
-31.8M
↓ 1.09%
Net Profit Margin
-440.51%
↑ 41.62%
Q4 FY22Q/Q Change
Revenue
8.2M
↑ 13.77%
Net Income
-38.7M
↑ 21.59%
Net Profit Margin
-470.81%
↓ 30.3%
Q1 FY23Q/Q Change
Revenue
7.4M
↓ 9.74%
Net Income
-37.1M
↓ 4.02%
Net Profit Margin
-500.66%
↓ 29.85%
Q2 FY23Q/Q Change
Revenue
8.7M
↑ 16.82%
Net Income
-38.9M
↑ 4.82%
Net Profit Margin
-449.23%
↑ 51.43%
Q3 FY23Q/Q Change
Revenue
9.3M
↑ 7.57%
Net Income
-112.6M
↑ 189.28%
Net Profit Margin
-1.2K%
↓ 758.82%
Q4 FY23Q/Q Change
Revenue
10.7M
↑ 15.06%
Net Income
-43.9M
↓ 61.01%
Net Profit Margin
-409.39%
↑ 798.66%
FY18Y/Y Change
Total Assets
24.8M
↑ 144.48%
Total Liabilities
14.7M
↓ 75.71%
FY19Y/Y Change
Total Assets
30.2M
↑ 21.79%
Total Liabilities
26.6M
↑ 81.66%
FY20Y/Y Change
Total Assets
60.4M
↑ 100.11%
Total Liabilities
25.4M
↓ 4.78%
FY21Y/Y Change
Total Assets
377.1M
↑ 523.83%
Total Liabilities
40.0M
↑ 57.61%
FY22Y/Y Change
Total Assets
307.5M
↓ 18.46%
Total Liabilities
58.1M
↑ 45.33%
FY23Y/Y Change
Total Assets
214.4M
↓ 30.28%
Total Liabilities
118.2M
↑ 103.51%
Q3 FY22Q/Q Change
Total Assets
323.7M
↑ 0.67%
Total Liabilities
42.0M
↑ 13.96%
Q4 FY22Q/Q Change
Total Assets
307.5M
↓ 5.0%
Total Liabilities
58.1M
↑ 38.49%
Q1 FY23Q/Q Change
Total Assets
292.2M
↓ 4.99%
Total Liabilities
60.7M
↑ 4.41%
Q2 FY23Q/Q Change
Total Assets
271.4M
↓ 7.11%
Total Liabilities
56.6M
↓ 6.66%
Q3 FY23Q/Q Change
Total Assets
181.9M
↓ 32.97%
Total Liabilities
62.9M
↑ 11.09%
Q4 FY23Q/Q Change
Total Assets
214.4M
↑ 17.87%
Total Liabilities
118.2M
↑ 87.98%
FY18Y/Y Change
Operating Cash Flow
-19.9M
↓ 4.2%
Investing Cash Flow
-331.7K
↓ 67.41%
Financing Cash Flow
35.8M
↑ 103.18%
FY19Y/Y Change
Operating Cash Flow
-29.5M
↑ 48.06%
Investing Cash Flow
-61.1K
↓ 81.59%
Financing Cash Flow
30.4M
↓ 15.09%
FY20Y/Y Change
Operating Cash Flow
-38.3M
↑ 29.75%
Investing Cash Flow
-2.4M
↑ 3912.63%
Financing Cash Flow
61.9M
↑ 103.76%
FY21Y/Y Change
Operating Cash Flow
-71.9M
↑ 87.73%
Investing Cash Flow
-278.1M
↑ 11249.69%
Financing Cash Flow
336.1M
↑ 442.98%
FY22Y/Y Change
Operating Cash Flow
-124.8M
↑ 73.53%
Investing Cash Flow
82.8M
↓ 129.77%
Financing Cash Flow
23.0M
↓ 93.15%
Q3 FY22Q/Q Change
Operating Cash Flow
-29.5M
↑ 4.03%
Investing Cash Flow
8.0M
↓ 74.54%
Financing Cash Flow
22.7M
↑ 11058.13%
Q4 FY22Q/Q Change
Operating Cash Flow
-34.5M
↑ 17.11%
Investing Cash Flow
11.6M
↑ 45.98%
Financing Cash Flow
146.0K
↓ 99.36%
Q1 FY23Q/Q Change
Operating Cash Flow
-32.4M
↓ 6.1%
Investing Cash Flow
16.5M
↑ 42.36%
Financing Cash Flow
14.9M
↑ 10079.45%
Q2 FY23Q/Q Change
Operating Cash Flow
-36.7M
↑ 13.21%
Investing Cash Flow
29.6M
↑ 78.94%
Financing Cash Flow
17.9M
↑ 20.31%
Q3 FY23Q/Q Change
Operating Cash Flow
-26.3M
↓ 28.35%
Investing Cash Flow
33.4M
↑ 13.02%
Financing Cash Flow
12.6M
↓ 29.6%

Technicals Summary

Sell

Neutral

Buy

Bionano Genomics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bionano Genomics Inc
Bionano Genomics Inc
-4.17%
-56.94%
-91.03%
-98.48%
-97.49%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
0.13%
40.36%
44.11%
46.9%
100.14%
Resmed Inc.
Resmed Inc.
-3.07%
31.59%
-17.23%
-10.51%
80.27%
Becton, Dickinson And Company
Becton, Dickinson And Company
-0.84%
-9.46%
-7.96%
-5.86%
-4.48%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-4.85%
-1.51%
4.42%
26.64%
225.06%
Alcon Ag
Alcon Ag
-5.4%
6.39%
13.12%
10.9%
45.79%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bionano Genomics Inc
Bionano Genomics Inc
NA
NA
NA
-6.61
-1.35
-0.33
NA
2.1
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
77.54
77.54
7.19
6.25
0.15
0.08
NA
37.77
Resmed Inc.
Resmed Inc.
32.03
32.03
1.88
7.41
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
55.27
55.27
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
49.53
49.53
6.9
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
42.12
42.12
4.62
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bionano Genomics Inc
Bionano Genomics Inc
Buy
$56.9M
-97.49%
NA
0.0%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$137.7B
100.14%
77.54
25.24%
Resmed Inc.
Resmed Inc.
Buy
$28.5B
80.27%
32.03
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$69.6B
-4.48%
55.27
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$28.5B
225.06%
49.53
20.12%
Alcon Ag
Alcon Ag
Buy
$40.7B
45.79%
42.12
10.3%

Institutional Holdings

  • Vanguard Group Inc

    3.46%
  • GMT Capital Corp

    0.97%
  • Renaissance Technologies Corp

    0.94%
  • BlackRock Inc

    0.92%
  • Two Sigma Investments LLC

    0.74%
  • Geode Capital Management, LLC

    0.69%

Corporate Announcements

  • Bionano Genomics Inc Earnings

    Bionano Genomics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o

Organization
Bionano Genomics Inc
Employees
344
CEO
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Industry
Health Technology

FAQs